Leslie Williams, MD
Family Medicine · Ormond Beach, FLNPI 1437563533
Payments from drug & device makers
Across 256 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$451
- AstraZeneca$375
- Lilly USA, LLC$304
- GSK$296
- Otsuka America Pharmaceutical, Inc.$276
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,12599%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 69 | $1,388 |
| Boehringer Ingelheim | 22 | $451 |
| AstraZeneca | 21 | $375 |
| Lilly USA, LLC | 17 | $304 |
| GSK | 16 | $296 |
| Otsuka America Pharmaceutical, Inc. | 9 | $276 |
| Bayer | 14 | $269 |
| AbbVie(2 entities) | 13 | $244 |
| Abbott | 11 | $214 |
| Amgen | 10 | $195 |
| Exact Sciences | 7 | $171 |
| Idorsia Pharmaceuticals US Inc | 4 | $162 |
| Pfizer | 7 | $127 |
| Merck | 7 | $109 |
| Renalytix AI, Inc. | 5 | $101 |
| Corium, LLC | 4 | $89 |
| Johnson & Johnson | 5 | $80 |
| Esperion Therapeutics, Inc. | 3 | $67 |
| Novartis | 2 | $42 |
| Dynavax Technologies Corporation | 1 | $33 |
| Insulet Corporation | 1 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $29 |
| Tolmar, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,188 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 159 | $197,467 |
| OzempicSemaglutide | 148 | $173,602 |
| MayzentSiponimod | 13 | $121,748 |
| EliquisApixaban | 138 | $120,495 |
| MounjaroTirzepatide | 104 | $118,046 |
| RybelsusSemaglutide | 72 | $103,519 |
| FarxigaDapagliflozin Propanediol | 73 | $77,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $58,109 |
| JanuviaSitagliptin Phosphate | 31 | $48,095 |
| XareltoRivaroxaban | 24 | $38,165 |
| LinzessLinaclotide | 27 | $34,812 |
| RexultiBrexpiprazole | 21 | $33,588 |
| WegovySemaglutide | 15 | $21,611 |
| ProliaDenosumab | 11 | $18,842 |
| Repatha SureclickEvolocumab | 25 | $18,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,388 | $298,732235 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $451 | $210,213176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $304 | $134,785116 claims |
| NovartisMayzent | $42 | $121,74813 claims |
| PfizerEliquis | $127 | $120,495138 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere | $375 | $97,972130 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $296 | $66,70880 claims |
| MerckJanuvia | $109 | $48,09531 claims |
| Johnson & JohnsonXarelto | $80 | $38,16524 claims |
| AbbVieLinzess, Synthroid | $244 | $38,03363 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $276 | $33,58821 claims |
| AmgenProlia | $195 | $18,84211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ormond Beach
- Diego Torres IiOrmond Beach$8.3M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.